Dual Receptor Recognizing Cell Penetrating Peptide for Selective Targeting, Efficient Intratumoral Diffusion and

Yayuan Liu1, Ling Mei1, Chaoqun Xu2

  • 11. Key Laboratory of Drug Targeting and Drug Delivery Systems, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu 610041, China.

Theranostics
|February 16, 2016
PubMed

Insights

A novel dual-receptor targeting peptide, R8-dGR, enhances drug delivery to gliomas. This peptide-modified liposomal system shows potent anti-tumor effects and improves survival in preclinical models.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Oncology

Background:

  • Cell penetrating peptides (CPPs) are used for tumor drug delivery but lack in vivo selectivity.
  • Malignant tumors often have poor prognosis due to extravascular core regions, necessitating improved targeting and diffusion.

Purpose of the Study:

  • To develop a novel peptide for targeted glioma therapy with enhanced cellular uptake and intratumoral diffusion.
  • To evaluate the efficacy of R8-dGR modified liposomes loaded with paclitaxel for glioma treatment.

Main Methods:

  • Conjugation of octa-arginine (R8) with dGR to create R8-dGR, a dual-receptor targeting peptide (integrin αvβ3 and neuropilin-1).
  • In vitro studies using glioma spheroids to assess cellular uptake and penetration.
  • In vivo studies using liposomal paclitaxel (PTX-R8-dGR-Lip) in intracranial C6 glioma-bearing mice.

Main Results:

  • R8-dGR demonstrated increased cellular uptake and efficient penetration into glioma spheroids.
  • PTX-R8-dGR-Lip exhibited strong anti-proliferation effects on tumor cells and cancer stem cells, inhibiting vasculogenic mimicry.
  • The R8-dGR liposomal system significantly prolonged survival in mice with intracranial gliomas (2.1-fold increase).

Conclusions:

  • R8-dGR is an effective dual-receptor targeting peptide with selective glioma targeting and enhanced intratumoral diffusion capabilities.
  • The R8-dGR liposomal drug delivery system offers a promising strategy for comprehensive glioma therapy.

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
94
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
107